Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Abstract Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Bibliographic Details
Main Authors: Kana Nagashima, Shohei Kikuchi, Satoshi Iyama, Chisa Fujita, Akari Goto, Hiroto Horiguchi, Masayoshi Kobune
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Clinical Case Reports
Subjects:
brentuximab vedotin
classical Hodgkin lymphoma
late‐relapse
Online Access:https://doi.org/10.1002/ccr3.2688

Internet

https://doi.org/10.1002/ccr3.2688

Similar Items